Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 13 of 65 · 3081 articles
Positive results and a planned Phase 2b study suggest ontunisertib is progressing in development for fibrostenosing Crohn’s disease — a condition with limited targeted therapies for intestinal fibrosis.
Cure8 found this source from app.dealroom.co, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib. Open the original article for the full details.
People with IBD who have failed multiple advanced therapies are often the most difficult to treat, yet this review shows they are under-represented in clinical trials. That limits direct evidence about how well new...
New biomarkers and cell-type insights could help future diagnostic tools or targeted therapies in UC by pointing to TRP channel–related genes and B/plasma cell involvement.
The study links a common compound in plant foods (oxalate) to intestinal inflammation in IBD, suggesting diet and oxalate metabolism may be modifiable contributors to flares.
The work helps explain why smoking increases Crohn’s risk but seems protective for ulcerative colitis by identifying genetic loci and smoking-dependent gene expression changes that differ between the two diseases. That...
The gut–liver axis links intestinal inflammation to liver disturbances in IBD. This preclinical study suggests a specific oat β‑glucan fraction reduced liver oxidative stress and inflammation in rats with chemically...
The work links a specific transcriptional regulator (GABPA) to STING-driven interferon and inflammatory responses and shows relevance to IBD and SLE patient samples, pointing to a potential new target for therapies aimed...
Patients with refractory IBD or those not fully responding to single targeted therapies may be interested because ACT aims to control multiple inflammatory pathways and could offer improved symptom and endoscopic...
Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Research and clinical trials.
Fibrostenosing (stricturing) Crohn’s disease is a major cause of complications and surgeries. Early-phase clinical results about a therapy targeting fibrotic strictures could matter to people facing strictures or...
If genetics helps explain who develops Crohn’s disease, better ways to pick the handful of important variants could speed discovery of biological mechanisms and future tests.
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.
Cure8 could only read part of this source from benzinga.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...
This report describes open‑label extension data for ontunisertib, an investigational oral drug being tested specifically for fibrostenosing Crohn’s disease.
This funding supports early-stage research that could identify new biological pathways and targets for treatment, which may eventually lead to more precise therapies or ways to prevent recurrence after surgery. It also...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib.
IBD patients often have depression and anxiety that current anti-TNF biologics do not adequately treat. An engineered probiotic that both neutralizes local TNFα and promotes GABA-producing microbes could address...
This study suggests an existing antimalarial drug, artemisinin, may reduce inflammation and improve gut barrier function in a mouse model of ulcerative colitis by targeting CD40 — a pathway relevant to immune-driven gut...
A colon-targeted delivery system could allow an anti-inflammatory plant extract (Myrica esculenta) to reach the colon with minimal systemic exposure, which may be relevant for developing localized treatments for...
Research funding supports early-stage studies that could identify new causes, targets, or tests for Crohn’s disease and ulcerative colitis. Progress in these areas may lead to more personalized treatments or prevention...
CDI is a common and serious complication in people hospitalized with IBD. Understanding whether CDI independently increases the risk of death, ICU care, or surgery — or mainly drives longer stays and higher costs — helps...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from nature.com.
The report suggests an investigational, gut-restricted ALK5 inhibitor (ontunisertib) had sustained symptom control, high remission rates, and few procedures or surgeries in an open-label extension for fibrostenosing...
Researchers increasingly implicate innate lymphoid cells in IBD inflammation and mucosal barrier breakdown — findings that could guide future diagnostics or therapies. For patients, this helps explain research directions...
The study identifies MrgprD on colonic macrophages as a driver of pro-inflammatory macrophage polarization and worse acute colitis in mice, highlighting a potential new pathway relevant to human IBD.
This study highlights macrophages — immune cells already suspected in IBD — and identifies MrgprD as a molecular driver in mouse colitis models, suggesting a new potential target that might one day lead to treatments...
Cure8 could only read part of this source from rttnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib.
Cure8 could only read part of this source from ground.news, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials.
Shortening ustekinumab dosing intervals raised drug levels and was associated with high rates of steroid-free clinical remission in this small prospective IBD cohort, offering a practical option for patients who lose...
If you have fibrostenosing Crohn’s disease, this investigational oral drug is being studied specifically for strictures — the company reports high CDAI remission in the extension and plans a larger randomized study...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib. Open the original article for the full details.
This registry will collect real-world data on guselkumab use in adults with moderate-to-severe Crohn's disease or ulcerative colitis, focusing on how long patients stay on treatment, effectiveness in routine practice,...
This trial examines whether a blueberry-rich supplement can change inflammation, the microbiome, and intestinal barrier function in people with chronic colitis — topics many with IBD care about because diet and the...
People with Crohn's disease often ask whether food additives and artificial sweeteners affect gut microbes or disease activity. This trial directly tests whether sucralose changes the fecal microbiome in adults with...
If gut microbes produce LPC/LPA that are linked to chronic abdominal pain, it could point to new biomarker or microbiome-targeted approaches for unexplained pain in IBD patients whose inflammation is quiet or minimal.
Patients with fibrostenosing Crohn’s disease have limited treatment options for the fibrotic strictures that can lead to procedures and surgery. These OLE findings suggest ontunisertib may be safe long-term and could...
Predicting which patients with acute severe ulcerative colitis will need colectomy or will not respond to steroids can guide early treatment decisions. This study shows that important predictors differ between East Asian...
Parents and clinicians often worry that when solids are started might change a child’s future risk of IBD. This large prospective study found no clear link between timing or patterns of complementary feeding and later...
AI models are being developed to support IBD care (activity scoring, risk prediction), but most studies are retrospective and don’t yet demonstrate that AI outputs reliably change clinical decisions or improve outcomes....
A new Phase 2 study of StemSmart™ could expand treatment options for patients with refractory or fistulising Crohn’s disease if later trials confirm safety and benefit. Appointment of a CRO is an early but important step...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Cell Biology and...
Simpler patient-reported scores (PRO2/PRO3) were much more often available in routine clinic visits than CDAI or HBI, yet they agreed closely with those indices. That could make regular monitoring and telehealth...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Ulcerative colitis, Inflammatory bowel disease, and Upadacitinib. The original article is from Clinical Gastroenterology and...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Free Radical Biology...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Pathology - Research...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Colloids and Surfaces...
